Literature DB >> 15000894

Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells.

Yun-feng Wan1, Xue-qing Guo, Zheng-hua Wang, Kang Ying, Ming-hui Yao.   

Abstract

AIM: To investigate the regulatory effect of paclitaxel on proliferation and apoptosis in human acute leukemia HL-60 cells.
METHODS: HL-60 cell growth was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tertrazolium bromide (MTT) colorimetric assay. Cell cycle kinetics and apoptosis were analyzed by flow cytometry and microscopic examination. In addition, DNA microarrays containing 14,400 EST elements were used to investigate the gene expression pattern of HL-60 cells exposed to paclitaxel 1 micromol/L.
RESULTS: Paclitaxel inhibited HL-60 cell growth significantly in a dose-dependent and time-dependent manner (P<0.01). Marked cell accumulation in G2/M phase and multinucleated cells were also observed after treatment with paclitaxel 0.1 and 1 micromol/L. Among 14400 EST elements, 277 genes were found to be markedly up- or down-expressed in the HL-60 cells treated with paclitaxel 1 micromol/L for 0.5 h, comprising 210 known genes and 67 unknown genes.
CONCLUSION: Paclitaxel suppresses the growth of HL-60 cells in vitro by causing cell-cycle arrest and apoptosis. The results of microarray suggest that paclitaxel initiates apoptosis through multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15000894

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  5 in total

1.  In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.

Authors:  V G Minero; D De Stefanis; P Costelli; F M Baccino; G Bonelli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Paclitaxel effects on the proteome of HL-60 promyelocytic leukemic cells: comparison to peloruside A.

Authors:  Anja Wilmes; Ariane Chan; Pisana Rawson; T William Jordan; John Holmes Miller
Journal:  Invest New Drugs       Date:  2010-09-23       Impact factor: 3.850

3.  Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.

Authors:  Antonio Silvani; Irene De Simone; Vittorio Fregoni; Elena Biagioli; Enrico Marchioni; Manuela Caroli; Andrea Salmaggi; Andrea Pace; Valter Torri; Paola Gaviani; Erica Quaquarini; Giorgia Simonetti; Eliana Rulli; Maurizio D'Incalci
Journal:  J Neurooncol       Date:  2019-02-06       Impact factor: 4.130

4.  Paclitaxel Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating Circ-BIRC6/miR-877-5p/YWHAZ Axis.

Authors:  Yi Liu; Jianchao Guo; Ka Shen; Renlong Wang; Cheng Chen; Zhiyuan Liao; Jianbo Zhou
Journal:  Onco Targets Ther       Date:  2020-09-22       Impact factor: 4.147

5.  MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel.

Authors:  Ronghua Liu; Xiaoming Liu; Yijie Zheng; Jie Gu; Shudao Xiong; Pei Jiang; Xuechao Jiang; Enyu Huang; Yixian Yang; DI Ge; Yiwei Chu
Journal:  Oncol Lett       Date:  2014-09-04       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.